The Supervisory Board of Medios AG has appointed Stefan Bauerreis as a member of the Executive Board and as the Company's new Chief Financial Officer, effective April 15, 2026. He succeeds Falk Neukirch, who will step down at his own request at the end of his regular term of office on April 30, 2026. This leadership transition comes as Medios positions itself for continued expansion in the specialty pharmaceutical sector.
Stefan Bauerreis brings extensive international finance experience to Medios, having served as Chief Financial Officer of the Stabilus Group and holding various senior finance positions within the Schaeffler Group for more than two decades. His roles included CFO for the Europe region and CFO for Germany, providing him with comprehensive expertise in Corporate Accounting, Controlling, Financing, and the transformation and management of international companies. This background is particularly relevant for Medios as it operates across multiple European markets including Germany, the Netherlands, Belgium and Spain.
Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Bauerreis combines operational excellence with strategic foresight and has demonstrated the ability to successfully lead companies through periods of transformation. The Supervisory Board believes he will provide important momentum for the future development of Medios, particularly as the company focuses on pioneering individualized medicine to make innovative therapies available through pharmacies, specialist practices and pharmaceutical companies.
For business and technology leaders, this appointment signals Medios's commitment to strengthening its financial leadership as it navigates the complex European pharmaceutical landscape. The company's focus on individualized medicine represents a growing trend in healthcare technology, where personalized treatments are becoming increasingly important. As Germany's first listed specialty pharmaceutical company, with shares listed on the regulated market of the Frankfurt Stock Exchange and included in the SDAX selection index, Medios's financial leadership decisions have implications for investors tracking the healthcare technology sector.
The timing of this appointment aligns with key corporate events in Medios's 2026 financial calendar, including the Metzler Small Cap Days in Frankfurt on April 15, the TP ICAP Midcap Conference in Paris on May 6, and the company's Capital Markets Day on September 28-29. These events will provide opportunities for the new CFO to outline his financial strategy for the company. More information about Medios's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine.
Stefan Bauerreis expressed his enthusiasm for the new role, stating that he looks forward to helping shape the future of Medios AG as part of the Executive Board. As CFO, he aims to contribute to further expanding the success of the Medios Group and its position as a leading Specialty Pharma company, both nationally and internationally. This leadership change occurs as the pharmaceutical industry faces increasing pressure to deliver personalized healthcare solutions while maintaining financial discipline, making experienced financial leadership particularly valuable for companies operating in this space.
